Clinical Trials on Esophageal Squamous Cell Carcinoma

Total 12970 results

Fudan University

Completed

A Study of SBRT for OligoMetastatic ESCC

Esophageal Squamous Cell Carcinoma Metastatic

China
RenJi Hospital

Recruiting

Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

Advanced Esophageal Squamous Cell Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Advanced Esophageal Squamous Cell Cancer

China
Peking University People's Hospital
Akeso Pharmaceuticals, Inc.

Not yet recruiting

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Xiangya Hospital of Central South University; Wuhan University; Zhujiang Hospital and other collaborators

Recruiting

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) (EC-CRT-007)

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Resectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study

Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital

Recruiting

Neo-NTP-CRT for Locally Advanced ESCC (Neo-NTP-CRT)

Locally Advanced Esophageal Squamous Cell Carcinoma

Taiwan
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Fudan University

Active, not recruiting

Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute
First Affiliated Hospital Xi'an Jiaotong University; General Hospital of Ningxia... and other collaborators

Unknown

Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Peking University

Unknown

Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Chemotherapy Effect | Esophageal Cancer, Squamous Cell | Cetuximab Effect

China
Zhejiang University

Withdrawn

Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma

Stage IV Esophageal Squamous Cell Carcinoma

China
University Hospital Ostrava

Completed

Chromoendoscopy to Detect Early Synchronous Second Primary Esophageal Carcinoma (HNSCC)

Squamous Cell Carcinomas of the Head and Neck

Czech Republic
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery

Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Esophageal Adenocarcinoma... and other conditions

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Korea, Republic of, Argentina, Denmark, France, Spain, Brazil, United Kingdom, Turkey, Czechia, Thailand, Russian Federation, Italy, Poland, Taiwan, Singapore, Ukraine, Kenya, Hungary
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC (Escape)

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

China
Zhigang Li
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

China
Fudan University
Shanxi Province Cancer Hospital; Jiangxi Provincial Cancer Hospital; Jiangsu... and other collaborators

Completed

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

Stage III Esophageal Squamous Cell Carcinoma

China
National Taiwan University Hospital

Unknown

Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC

Stage III Esophageal Squamous Cell Carcinoma

Taiwan
The First Affiliated Hospital of Henan University...
The First Affiliated Hospital of Zhengzhou University; No. 150 Central Hospital... and other collaborators

Unknown

The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy (DCOECRT)

Esophageal Neoplasms | Stage III Esophageal Squamous Cell Carcinoma

China
Mona Frolova

Unknown

Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer

Esophageal Neoplasms | Squamous Cell Carcinoma | Concurrent Chemoradiotherapy

Russian Federation
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Adenocarcinoma | Recurrent Gastric Carcinoma | Esophageal Undifferentiated Carcinoma | Gastric Squamous Cell Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IV Esophageal Adenocarcinoma | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
Zhejiang Cancer Hospital

Recruiting

Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (Stars)

Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma

China
Chongqing University Cancer Hospital

Not yet recruiting

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

PARP Inhibitor for Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital

Recruiting

Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

Locally Advanced Esophageal Squamous Cell Carcinoma

Taiwan
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Zhongshan People's Hospital... and other collaborators

Recruiting

Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) (EC-CRT-002)

Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Hebei Medical University Fourth Hospital

Unknown

A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

Refractory or Metastatic Esophageal Squamous Cell Carcinoma

China
Daping Hospital and the Research Institute of Surgery...

Recruiting

PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY

Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes

China
The First People's Hospital of Changzhou

Not yet recruiting

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
BeiGene

Active, not recruiting

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

United States, China, Spain, Australia, Czechia, Japan, Belgium, Korea, Republic of, Italy, Germany, France, Romania, Poland, United Kingdom, Russian Federation, Taiwan
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Radiotherapy | Sintilimab | Concurrent Chemoradiotherapy | Immunonutrition | Locally Advanced Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University

Unknown

A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma

Stage II and III Esophageal Squamous Cell Carcinoma

China
University of California, San Francisco
Johns Hopkins University; National Cancer Institute (NCI); Muhimbili University... and other collaborators

Recruiting

Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Esophageal Squamous Dysplasia

Tanzania
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Esophageal Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Zhejiang University

Withdrawn

Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma

Stage IV Esophageal Squamous Cell Carcinoma

China
Peking University

Recruiting

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Esophageal Squamous Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Unknown

Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
The Central Hospital of Lishui City

Not yet recruiting

Immunotherapy After Radiotherapy in Elderly ESCC (TREE)

Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Shanghai Zhongshan Hospital
Ruijin Hospital; Tianjin Medical University Cancer Institute and Hospital; Shanghai... and other collaborators

Completed

Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC (ESCCNCRTvNCT)

Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0

China
Sun Yat-sen University

Active, not recruiting

Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy

Esophageal Cancer

China
Centre Oscar Lambret

Unknown

Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer (E-DIS2)

Esophageal Cancer, Squamous Cell

France
Mian XI

Recruiting

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma | Neoplasm, Esophageal

China
Peking Union Medical College Hospital

Not yet recruiting

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Anlotinib | Advanced Esophageal Squamous Cell Cancer | SHR-1210
Sun Jing

Not yet recruiting

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Locally Advanced Esophageal Squamous Cell Carcinoma

Clinical Trials on Esophageal Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations